As with selumetinib, a second therapeutic strategy sought to enhance RAI uptake in refractory thyroid cancers by leveraging vemurafenib-induced redifferentiation seen in genetically engineered mouse models with conditional BRAF V600E activation (42). Here, BRAF is linked to thyroid cancer.